Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders

Nature Medicine volume 29, pages 2993–2995 (2023)Cite this article

Subjects

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Klausen, M. K. et al. Br. J. Pharmacol. 179, 625–641 (2022).

    Article  PubMed  Google Scholar 

  2. Chuong, V. et al. JCI Insight 8, e170671 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Aranäs, C. et al. eBioMedicine 93, 104642 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Suchankova, P. et al. Transl. Psychiatry 5, e583 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Farokhnia, M. et al. Sci. Rep. 12, 13027 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Farokhnia, M. et al. Addict. Biol. 27, e13211 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Wium-Andersen, I. K. et al. Basic Clin. Pharmacol. Toxicol. 131, 372–379 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Klausen, M. K. et al. JCI Insight 7, e159863 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Angarita, G. A. et al. Drug Alcohol Depend. 221, 108614 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yammine, L. et al. Nicotine Tob. Res. 23, 1682–1690 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Witkiewitz, K. et al. Sci Adv. 5, eaax4043 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Han, B. et al. JAMA Psychiatry 78, 922–924 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Clarke, T. K. et al. Mol. Psychiatry 22, 1376–1384 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Jonas, D. E. et al. JAMA 311, 1889–1900 (2014).

    Article  PubMed  Google Scholar 

  15. Vancampfort, D. et al. Alcohol Alcohol. 51, 515–521 (2016).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the following funding sources: NIDA and NIAAA Intramural Research Programs (L.L. and M.F.); NIAAA grant R21AA026931 and NIDA grant R21DA047663 (C.H.); the Research Fund of the Mental Health Services – Capital Region of Denmark (M.K.K.), the Novo Nordisk Foundation (M.K.K. and A.F.J.), NIAAA grants R01AA027765, R01AA026859, and R21 AA031146 (J.P.S.); the Hardesty Family Foundation (W.K.S.).

Author information

Authors and Affiliations

  1. Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, MD, USA

    Lorenzo Leggio & Mehdi Farokhnia

  2. Bowles Center for Alcohol Studies and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Christian S. Hendershot

  3. Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen, Denmark

    Anders Fink-Jensen & Mette Kruse Klausen

  4. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Anders Fink-Jensen

  5. Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA

    Joseph P. Schacht

  6. Department of Pharmacology & Physiology, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA

    W. Kyle Simmons

  7. OSU Biomedical Imaging Center, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA

    W. Kyle Simmons

Authors
  1. Lorenzo Leggio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian S. Hendershot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehdi Farokhnia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anders Fink-Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mette Kruse Klausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joseph P. Schacht
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Kyle Simmons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorenzo Leggio.

Ethics declarations

Competing interests

L.L. reports, outside his federal employment, honoraria from the UK Medical Council on Alcohol (editor-in-chief for Alcohol and Alcoholism) and book royalties from Routledge (as editor of a textbook). A.F.J. has received two unrestricted research grants from Novo Nordisk A/S for two clinical studies investigating the effects of GLP-1RAs in antipsychotic-treated prediabetic patients with schizophrenia. J.P.S. has received study medication from Bausch Health. The other authors report no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leggio, L., Hendershot, C.S., Farokhnia, M. et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med 29, 2993–2995 (2023). https://doi.org/10.1038/s41591-023-02634-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02634-8

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing